Spiramycinisamacrolideantibioticthatisclinicallyusedtotreattoxoplasmosisandothersofttissueinfections.SpiramycinexhibitsantibacterialefficacyagainstToxoplasma,inhibitingbacterialproteinsynthesis.Invitro,spiramycindecreaseslevelsofIL-10andTNF-α,andinvivo,itdecreasesToxoplasma-inducedbraincysts.
| CasNo. | 8025-81-8 |
|---|---|
| Purity | ≥3900IU/mg |
| Formula | C43H74N2O14 |
| FormulaWt. | 842.05 |
| IUPACName | 2-[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-6-[5-(4,5-dihydroxy-4,6-dimethyloxan-2-yl)oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-1-oxacyclohexadeca-11,13-dien-7-yl]acetaldehydeInChI:InChI=1S/C43H74N2O14/c1-24-21-29(19-20-46)39(59-42-37(49)36(45(9)10)38(27(4)56-42)58-35-23-43(6,51)41(50)28(5)55-35)40(52-11)31(47)22-33(48)53-25(2)15-13-12-14-16-32(24)57-34-18-17-30(44(7)8)26(3)54-34/h12-14,16,20,24-32,34-42,47,49-51H,15,17-19,21-23H2,1-11H3/b13-12+,16-14+/t24-,25-,26?,27?,28?,29+,30?,31-,32+,34?,35?,36?,37?,38?,39+,40+,41?,42?,43?/m1/s1 |
| Synonym | Selectomycin;rovamicina;rovamycin;RP-5337 |
| Solubility | Slightlysolubleinwater.Solubleinmostorganicsolvents,DMSO. |
| Appearance | WhiteorSlightlyYellowPowder |
| StoreTemp | Ambient |
|---|---|
| ShipTemp | Ambient |
| MSDS | S6232MSDSPDF |
|---|---|
| InfoSheet | S6232InfoSheetPDF |
KiefferF,WallonM.Congenitaltoxoplasmosis.HandbClinNeurol.2013;112:1099-101.PMID:23622316.
BüyükbabaBoralO,SönmezTamerG,KeçeliÖzcanS,etal.Investigationofcombinedeffectivenessofspiramycinandbeta-glucaninmicemodelsofacutetoxoplasmosisanddeterminationofIL-10,IL-12andTNF-αlevels.MikrobiyolBul.2012Jul;46(3):446-55.PMID:22951656.
ChewWK,SegarraI,AmbuS,etal.SignificantreductionofbraincystscausedbyToxoplasmagondiiaftertreatmentwithspiramycincoadmiNISTeredwithmetronidazoleinamousemodelofchronictoxoplasmosis.AntimicrobAgentsChemother.2012Apr;56(4):1762-8.PMID:22271863.
